Pair Name | Tiliroside, Sorafenib | ||
Phytochemical Name | Tiliroside (PubChem CID: 5320686 ) | ||
Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Tiliroside, Sorafenib | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Ferroptosis | |||
Gene Regulation | Down-regulation | Expression | FTH1 | hsa2495 |
Down-regulation | Expression | G6PD | hsa2539 | |
Down-regulation | Expression | GPX4 | hsa2879 | |
Up-regulation | Expression | KEAP1 | hsa9817 | |
Down-regulation | Expression | NFE2L2 | hsa4780 | |
Up-regulation | Expression | SQSTM1 | hsa8878 | |
Down-regulation | Phosphorylation | TBK1 | hsa29110 | |
In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
In Vivo Model | A total of 2.5×10⁶ HepG2-luciferase cells/100 µl were injected into the left axilla of mice. | |||
Result | Our findings imply that tiliroside is a potent TBK1 inhibitor and a candidate natural anti-cancer product that could function as a sensitizer of sorafenib in HCC treatment by targeting TBK1 to induce ferroptosis. |
No. | Title | Href |
---|---|---|
1 | Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib. Phytomedicine. 2023 Mar;111:154668. doi: 10.1016/j.phymed.2023.154668. | Click |